Sonkar Roshan, Jha Abhishek, Viswanadh Matte Kasi, Burande Ankita Sanjay, Pawde Datta Maroti, Patel Krishna Kumar, Singh Mamata, Koch Biplob, Muthu Madaswamy S
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, India.
Genotoxicology and Cancer Biology Lab, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111652. doi: 10.1016/j.msec.2020.111652. Epub 2020 Oct 20.
This work was aimed to formulate transferrin (Tf) receptor targeted gold based theranostic liposomes which contain both docetaxel (DCX) and glutathione reduced gold nanoparticles (AuGSH) for brain-targeted drug delivery and imaging. AuGSH was prepared by reducing chloroauric acid salt using glutathione. The co-loading of DCX and AuGSH into liposomes was achieved by the solvent injection technique, and Tf was post-conjugated on the surface of the liposomes using carboxylated Vit-E TPGS (TPGS-COOH) as a linker. The liposomes were characterized for various parameters such as size, shape, surface charge, and drug release. The Tf receptor targeted gold liposomes were evaluated for the cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) based colorimetric assay and in-vitro qualitative cellular uptake studies using confocal microscopy. The in-vivo site specific delivery of DCX was analyzed by the brain distribution study of DCX in comparison with marketed formulation (Docel™). A sustained drug release of about 70% was observed from liposomes in the span of 72 h. The in-vivo results demonstrated that targeted gold liposomes were able to deliver DCX into the brain by 3.70, 2.74 and 4.08-folds higher than Docel™ after 30, 120 and 240 min of the treatment, respectively. Besides, the results of these studies have suggested the feasibility of Tf decorated AuGSH and DCX co-loaded liposomes as a promising platform for targeted nano-theranostics.
本研究旨在制备转铁蛋白(Tf)受体靶向的金基诊疗脂质体,其同时包含多西他赛(DCX)和谷胱甘肽还原金纳米颗粒(AuGSH),用于脑靶向给药和成像。通过用谷胱甘肽还原氯金酸盐制备AuGSH。采用溶剂注入技术将DCX和AuGSH共载入脂质体,并使用羧化维生素E TPGS(TPGS-COOH)作为连接剂将Tf后共轭到脂质体表面。对脂质体的各种参数进行了表征,如大小、形状、表面电荷和药物释放。通过基于3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)的比色法和使用共聚焦显微镜的体外定性细胞摄取研究,评估了Tf受体靶向金脂质体的细胞毒性。通过与市售制剂(Docel™)比较DCX的脑分布研究,分析DCX在体内的位点特异性递送。在72小时内观察到脂质体持续释放约70%的药物。体内结果表明,在治疗30、120和240分钟后,靶向金脂质体将DCX递送至脑内的量分别比Docel™高3.70、2.74和4.08倍。此外,这些研究结果表明,Tf修饰的AuGSH和DCX共载脂质体作为一种有前景的靶向纳米诊疗平台具有可行性。